MedWatch

Lundbeck cancels Alzheimer’s drug

Following last week's rejection of Lundbecks’s Alzheimer’s candidate, Acrescent, the company has decided to cancel clinical development of the drug.

Foto: PR Lundbeck

With its rejection of marketing approval for Acrescent the European Medicines Agency (EMA) has effectively halted any further development of the project.

“Lundbeck is not going to pursue the project further or do anything to try and change the decision from the EMA committee, because it is a small project involving high risks,” Lundbeck’s International Media Specialist Mads Augustensen tells Medwatch.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier